FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumours By Ogkologos - September 2, 2026 84 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-001 and LIBRETTO-121 studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL Meet the first recipient of the ESMO Artificial Intelligence Fellowship MOST POPULAR Lisocabtagene Maraleucel in Relapsed or Refractory Large B-cell Lymphomas September 7, 2020 FDA Approves Erdafitinib for Locally Advanced or Metastatic Urothelial Carcinoma February 2, 2024 Ivonescimab Plus Chemotherapy Significantly Improves PFS in Patients with NSCLC Previously... June 19, 2024 EMA Recommends Extension of Therapeutic Indications for Ponatinib February 27, 2026 Load more HOT NEWS Coverage for Breast Cancer Genetic Marker Testing is Still Being Denied... Researchers Create Modified Antibodies to Target RAS and p53 in Cancer FDA Grants Accelerated Approval to Sotorasib for KRAS G12C-mutated NSCLC Cancer Research UK spin-out gets US approval to trial unique T...
